Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis

Tianshi Mao,Jie Chen,Tong Su,Long Xie,Xinyan Qu,Ruli Feng,Yi Pan,Jie Wan,Xiaoyun Cui,Wenhao Jia,Qun Gao,Qian Lin
DOI: https://doi.org/10.1186/s13098-024-01448-z
2024-09-01
Diabetology & Metabolic Syndrome
Abstract:Glucagon-like peptide-1 receptor (GLP1R) agonists have been shown to reduce major cardiovascular events in diabetic patients, but their role in heart failure (HF) remains controversial. Recent evidence implies their potential benefits on cardiometabolism such as lipid metabolism, which may contribute to lowering the risk of HF. Consequently, we designed a Mendelian randomization (MR) study to investigate the causal relationships of circulating lipids mediating GLP1R agonists in HF.
endocrinology & metabolism
What problem does this paper attempt to address?